CGON
Cg Oncology, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$64.68Close
$5.2BMarket cap
$37.37 – $80.6852-week range
Nov 13, 2026Next report
Highlights
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Results soon Nov 13, 2026, in 12 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
20%
1wk
up 4.8%
price change
1mo
down 8.8%
price change
12-month return
up 52%
market up 11% ·
its own up 40%
F-score
—
— Not assessed
Altman Z
79.96
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
6.9×
price / book
Earnings yield
down 3.7%
EBIT / enterprise value
Cheaper than
19%
of the market · expensive
Revenue growth
up 255%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 22%
return on equity
Free cash margin
down 3279%
-$132.5M FCF
D/E
0.00
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.4%
$2.87 a day · 2×ATR $58.94
RS
66 / 99
vs the universe
Trend
5 / 8
under the 150/200-day, under the 50-day, RS under 70
Relative volume
1.0×
vs 50-day average
Up/down volume
0.95
50 sessions
Implied move
—
no option chain · report Nov 13, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 6.0% over the year, from 76m to 81m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+3% vs market2 sessions after results
Financials
- Net -3985%
- Free cash -3279%
- Cash
- Long-term debt
| FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|
| Revenue | $204,000 | $1.1M | $4.0M |
| Operating income | -$55.4M | -$114.7M | -$190.8M |
| Net income | -$48.6M | -$88.0M | -$161.0M |
| Net margin | -23827% | -7730% | -3985% |
| Earnings per share | -$11.22 | -$1.41 | -$2.08 |
| Free cash flow | -$45.7M | -$78.9M | -$132.5M |
| Free cash margin | -22392% | -6931% | -3279% |
| Cash | $8.3M | $257.1M | $32.5M |
| Long-term debt | — | $0 | $3.0M |
| Shareholders' equity | -$123.1M | $733.4M | $752.6M |
| Shares outstanding | 5.22m | 76.15m | 80.69m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Nov 14, 2025 | Quarterly ↗ | Sep 30, 2025 | 45d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 28, 2025 | Annual ↗ | Dec 31, 2024 | 87d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results · Other events ↗ |
| Jun 8, 2026 | Shareholder vote ↗ |
| May 26, 2026 | Director or officer change ↗ |
| May 8, 2026 | Results ↗ |
| Apr 13, 2026 | Director or officer change ↗ |
| Feb 27, 2026 | Results ↗ |
| Jan 13, 2026 | Other events ↗ |
| Jan 9, 2026 | Regulation FD · Other events ↗ |
| Nov 26, 2025 | Director or officer change ↗ |
| Nov 14, 2025 | Director or officer change ↗ |
| Nov 14, 2025 | Results ↗ |
| Sep 9, 2025 | Regulation FD ↗ |